Markets
Strong and muscular bull in spain
Strong and muscular bull in Spain

S&P 500 closes at record despite Nvidia’s post-earnings dip

A fresh record close for the benchmark US stock index.

Nia Warfield, Luke Kawa
8/28/25 3:40PM

The S&P 500 posted another record close, rising 0.3% on Thursday. That’s despite the biggest stock in the world, Nvidia, falling a little less than 1% after reporting solid but unspectacular Q2 results.

The Nasdaq 100 outperformed with a 0.6% advance while the Russell 2000 rose 0.2%.

Tech was the best-performing S&P sector ETF, while defensive pockets of the market like utilities, consumer staples, healthcare, and real estate all declined.

Gains on the day were led by Datadog and Fair Isaac, which rose 7% and 6.2%, respectively. Hormel Foods was at the bottom of the S&P 500’s leaderboard, sinking 13% after the company missed Q3 earnings estimates and warned that higher commodity price were weighing on profits. Elsewhere…

Pure Storage shares soared 32%, just inches from a record high, after the data storage company issued a beat-and-raise Q2 earnings report.

Build-A-Bear soared 14.7% after posting record Q2 earnings and revenue, raising its outlook as it opens more than a dozen new stores and scales back promotions.

CoreWeave climbed 6% after Nvidia’s light Q2 data center miss was chalked up to supply constraints, a positive for CoreWeave, which provides overflow GPU access.

Burlington Stores shares jumped 5.4% after the off-price retailer reported second-quarter results that beat Wall Street forecasts and raised its full-year guidance.

Victoria’s Secret shares rose as much as 9% before ending flat after the intimates retailer posted strong Q2 results and raised its full-year sales outlook. Similarly...

Dollar General rose as much as 2% before closing flat after the discount chain crushed Q2 earnings and boosted its full-year profit guidance.

Best Buy shares fell 3.7% after the electronics retailer delivered a solid Q2 as shoppers picked up more gadgets, but held its full-year guidance steady as tariffs loom.

Bath & Body Works shares fell 6.9% after the lotion and soap maker posted mixed Q2 results, with shoppers still stocking up but rising administrative and store costs eating into profits.

More Markets

See all Markets
markets
Luke Kawa
9/5/25

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.